Epidemiological Investigation of COVID-19 in Laos Using a One-Health Approach in Human and Animals (LACOVISS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04716543|
Recruitment Status : Not yet recruiting
First Posted : January 20, 2021
Last Update Posted : July 1, 2021
The Respiratory infection COVID-19, due to a new coronavirus, SARS-CoV2, appeared in December 2019 in several people who attended the wildlife market in Wuhan, Hubei Province, China. While COVID-19 has spread to nearly 200 countries and caused two millions infections, Lao PDR detected its first confirmed case very recently, on March 20, three months after the start of the outbreak in China. As of April 12th, 2020, Lao PDR has only recorded 18 confirmed cases, a very low number compared to other countries around the world.
However, several key factors suggest that Lao PDR could be much more affected by COVID-19 because of the following reasons: (i) The multiple and massive trans-border movements between Lao PDR and China. (ii) The similar biogeographical and socio-ecological characteristics with South-Western China. (iii) The detection of a high diversity of Betacoronavirus sequences in several species of bats in Lao PDR. (iv) The numerous markets selling high volumes of local wildlife including bats and pangolins.
LACOVISS project aim at investigating, using a ONE-HEALTH approach, this unexpected epidemiological pattern of SARS-CoV-2 in Lao PDR by bringing together an interdisciplinary team of experts in the field from IRD, the University of Caen, the Center of Infectiology Lao-Christophe Mérieux (CILM) and the National animal Health Laboratory (NAHL) in Vientiane. The study will focus on a community-based cohort of 1092 households, including 5400 study participants, followed-up between March 2015 and February 2019 for influenza-like illness investigation and causative agents detection (LACORIS project), located in the Vientiane metropolitan area. The COVID-19 progression in Lao PDR, and track SARS-CoV-2, will be followed retrospectively and prospectively, in all potential actors in SARS-CoV-2 circulation, including humans, domestic animals, and wildlife.
The LACOVISS project will undoubtedly bring new insight in SARS-Cov-2 and SARS-CoV-like circulation in Lao PDR as well as valuable information on the natural history of COVID-19, and on the modalities of the spillover into humans, which are still largely unknown.
|Condition or disease||Intervention/treatment|
|Influenza -Like Illness Covid19||Diagnostic Test: ILI and COVID-19 detection|
|Study Type :||Observational|
|Estimated Enrollment :||5400 participants|
|Official Title:||One-health Approach in Epidemiological Investigation of SARS-CoV-2 in Laos|
|Estimated Study Start Date :||August 1, 2021|
|Estimated Primary Completion Date :||March 2022|
|Estimated Study Completion Date :||March 2022|
The suspected ILI cases will be first identified using the WHO clinical case definition of ILI and Covid 19 as either with:Acute onset of fever (> 37.5˚C axillary temperature or > 38˚C tympanic temperature) AND cough; OR Acute onset of ANY ONE OR MORE of the following signs or symptoms: Fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anosmia (loss of smell) or ageusia (loss of taste); with symptoms with onset within the last 10 days.
Diagnostic Test: ILI and COVID-19 detection
All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.
All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.
- Prevalence of SARS-CoV-2 RNA in respiratory samples collected from influenza-like illness patients from cohort study 2020-2021 [ Time Frame: Months 12 ]Number of participants SARS-CoV-2 positive among total number of participants tested
- Prevalence of SARS-CoV-2 RNA in respiratory samples from influenza-like illness patients from cohort study between 2015 and 2019 [ Time Frame: Months 12 ]Number of respiratory samples positive for SARS-CoV-2 over the total number of respiratory samples from the 2015-2019 cohort
- Prevalence of SARS-CoV-2 RNA in respiratory samples from intrafamilial contacts of influenza-like illness patients (2020-2021) [ Time Frame: Months 12 ]Number of SARS-CoV-2 positive samples among the total number of samples collected from participants living within the family nucleus of influenza-like illness patients
- Prevalence of SARS-CoV-2 IgG among 1000 individuals randomly selected from the 2020-2121 study cohort. IgG will be assayed in saliva samples [ Time Frame: Months 12 ]Number of participants IgG positive over a thousand, randomly selected, participants tested.
- Prevalence of SARS-CoV-2 RNA in respiratory and faecal samples collected from companion animals living with influenza-like illness patients [ Time Frame: Months 12 ]Number of pet animals positive for SARS-CoV-2 over the total number of pets tested
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04716543
|Contact: Eric M LEROY, DVM, PhD||+33 firstname.lastname@example.org|
|Contact: Sabrina LOCATELLI, PhD||+33 email@example.com|
|Principal Investigator:||Phimpha PABORIBOUNE, MD, PhD||Centre d'Infectiologie Lao-Christophe Mérieux|